CTIS2023-505098-34-00招募中1 期
A Phase IV Longitudinal Study of SUBLOCADE (SUBUTEX Prolonged Release) Clinical Outcomes in Adults with Opioid Use Disorder (Opioid Dependence) - INDV-6000-406
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Is an adult = 18 years of age who has signed the ICF, Plans to receive additional SUBLOCADE injections and has initiated treatment for OUD/opioid dependence with SUBLOCADE within the last 3 months prior to Baseline Visit OR has completed an Indivior SUBLOCADE study (eg, INDV-6000-401, INDV-6000-405) and has received the last dose of SUBLOCADE on that study within 3 months prior to Baseline Visit
排除标准
- •Patient participating in any clinical trial requiring medical intervention, Patient currently using opioids to treat a diagnosis other than OUD/opioid dependence
研究者
相似试验
进行中（未招募）
1 期
A multicentre, open label Phase IV study of subcutaneously administered efalizumab in the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant of other systemic therapies including cyclosporin, methotrexate and PUVA. - efalizumab physician experience studyEUCTR2004-001236-23-IESerono International S.A.1,500
进行中（未招募）
不适用
A prospective, multi-center phase II study of subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allogeneic stem-cell transplantation, in chronic lymphocytic leukemia which is associated with 17p deletion or is refractory to fludarabine. - CLL2O Protocol of the German CLL Study Group (GCLLSG)Patient with chronic lymphocytic leukemia (CLL) requiring therapy with a high risk factor such as 17p deletion or refractoriness to fludarabine .MedDRA version: 9.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaMedDRA version: 9.1Level: LLTClassification code 10008978Term: Chronic lymphocytic leukemia refractoryEUCTR2007-003099-20-DEniversitätsklinikum Ulm122
进行中（未招募）
不适用
A prospective, multi-center phase II study of subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allogeneic stem-cell transplantation, in chronic lymphocytic leukemia which is associated with 17p deletion or is refractory to fludarabine. - CLL2O Protocol of the German CLL Study Group (GCLLSG)EUCTR2007-003099-20-ATniversitätsklinikum Ulm95
进行中（未招募）
不适用
A prospective, multi-center phase II study of subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allogeneic stem-cell transplantation, in chronic lymphocytic leukemia which is associated with 17p deletion or is refractory to fludarabine. - CLL2O Protocol of the German CLL Study Group (GCLLSG)Patient with chronic lymphocytic leukemia (CLL) requiring therapy with a high risk factor such as 17p deletion or refractoriness to fludarabine .MedDRA version: 9.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaMedDRA version: 9.1Level: LLTClassification code 10008978Term: Chronic lymphocytic leukemia refractoryEUCTR2007-003099-20-FRniversitätsklinikum Ulm95
进行中（未招募）
1 期
A Clinical Study with Investigational Drug, ALN-CC5, in patients with Paroxysmal Nocturnal Hemoglobinuria who are Inadequate Responders to EculizumabEUCTR2016-002943-40-ESAlnylam Pharmaceuticals Inc15